My NCBISign In
Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants
Gaetano Chirico, Roberto Ravasio, Urbano Sbarigia
Ital J Pediatr. 2009; 35: 4. Published online 2009 February 25. doi: 10.1186/1824-7288-35-4
PMCID:
PMC2687544
Abstract Full Text PDF–532K

Is Cited by the Following 2 Articles in this Archive:

A decade of respiratory syncytial virus epidemiology and prophylaxis: Translating evidence into everyday clinical practice
Bosco A Paes, Ian Mitchell, Anna Banerji, Krista L Lanctôt, Joanne M Langley
Can Respir J. 2011 Mar-Apr; 18(2): e10–e19.
PMCID:
PMC3084427
Abstract Full Text PDF–581K
Economic results of a palivizumab seasonal prophylaxis using a cohorting software and vial sharing
Elio Coletta, Salvatore Coppolino, Febronia Federico, Francesco Fulia
Ital J Pediatr. 2010; 36: 48. Published online 2010 July 7. doi: 10.1186/1824-7288-36-48
PMCID:
PMC2909955
Abstract Full Text PDF–314K
You are here: NCBI > Literature > PubMed Central (PMC)
Write to the Help Desk